ArticleFrontiers in pharmacology2025
Topical prevention from high energy visible light-induced pigmentation by 2-mercaptonicotinoyl glycine, but not by ascorbic acid antioxidant: 2 randomized controlled trials.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the efficacy of an antimelanogenesis agent (melasyl) in different concentrations under part of visible light [400-450nm] exposures and under full visible light [400-700nm] exposures
Evaluation of the efficacy of antipigmenting or depimenting agents under part of visible light [400-450nm] exposures
Who cites it
4 citing papers in PubMed.
- Beyond Tint: Active Ingredient Strategies for Post-Inflammatory Hyperpigmentation due to Visible Light in Skin of Color.Photodermatology, photoimmunology & photomedicine · 2026Review
- Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications.Dermatology and therapy · 2026Review
- Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review.Dermatology and therapy · 2026Review
- Beyond the boundaries of pigmentation and inflammation: understanding the mechanistic basis of melasma-rosacea comorbidity.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hyperpigmentation and pigmentary disorders are major clinical consequences of sun exposure. While UV radiation is a known contributor, visible light (VL), particularly High Energy Visible (HEV) light (400-450 nm), also induces long-lasting pigmentation in melanocompetent individuals (Fitzpatrick Phototype III and above), and can worsen pigmentary disorders. Therefore, photoprotection in this wavelengths range is recommended to prevent worsening of hyperpigmentation issues. Efficient solutions rely on the use of pigments, absorbing and diffusing VL. However, tint and opacity of these products may limit their use by consumers and patients. The search for actives preventing VL-induced pigmentation is therefore of interest. This work aimed at assessing 2 non tinted biological actives to counteract HEV-induced pigmentation. Material and Methods: Two very potent inhibitors of UV-induced pigmentation, ascorbic acid 7% (powerful antioxidant) and 2-mercaptonicotinoyl glycine (2-MNG, 0.5 or 1%, melanogenesis inhibitor), were assessed in 2 controlled randomized clinical trials (registered under the identification numbers NCT06945393 and NCT06937515 on ClinicalTrials.gov), including in total, 58 individuals with Fitzpatrick Phototype III or IV. Delineated areas on the subjects back, topically treated or not by the product, were exposed to HEV once a day for 4 days. The product was applied before, during and 5 weeks after HEV exposure. Pigmentation was assessed using chromametry and visual scoring throughout the studies. Results: While ascorbic acid did not exhibit any efficacy versus its vehicle in limiting skin hyperpigmentation induced by HEV, the use of 2-MNG (0.5 or 1%) led to an early significant decrease in HEV-induced pigmentation, which was sustained until the end of the study, as evidenced by colorimetry and significantly scored by visual assessment. Moreover, a 2-MNG dose effect could be evidenced at early time points. Conclusion: 2-MNG represents an efficient and transparent alternative solution to pigments for the mitigation of HEV worsening of hyperpigmentation issues. This opens up perspectives for its use as a complement to UV protection afforded by sun filters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.